STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	May 31, 2024	May 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (371,332)	$ (287,405)
Adjustments to reconcile net loss to net cash used by operating activities:
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D.	210,070	166,097
Changes in operating assets and liabilities
Prepaids	300	300
Accounts payable	61,595	10,187
Accrued liabilities	39,837	45,518
NET CASH USED BY OPERATING ACTIVITIES	(59,530)	(65,303)
CASH FLOWS FROM FINANCING ACTIVITIES
Contribution of capital	58,517	64,517
NET CASH PROVIDED BY FINANCING ACTIVITIES	58,517	64,517
NET DECREASE IN CASH	(1,013)	(786)
CASH AT BEGINNING OF PERIOD	1,310	934
CASH AT END OF PERIOD	$ 297	$ 148